ARS Pharmaceuticals, Inc. (SPRY) reported a quarterly loss of $0.42 per share for the period ending December 2025, aligning with the Zacks Consensus Estimate and down from earnings of $0.52 per share a year ago. This reflects an earnings surprise of -0.96%. The company’s revenues for the quarter were $28.09 million, exceeding expectations by 9.10% but significantly lower than $86.58 million reported in the same quarter last year.
Over the past four quarters, ARS Pharmaceuticals has consistently fallen short of consensus EPS estimates. The stock has seen a decline of approximately 22.2% year-to-date, compared to a 1.5% drop in the S&P 500. Looking forward, the current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $25.86 million, with an overall annual estimate of -$1.41 on $177.14 million in revenues.
In the competitive landscape, Guardian Pharmacy Services (GRDN), another player in the same industry, is anticipated to report earnings on March 11, 2026. Analysts expect GRDN to achieve an EPS of $0.27 and revenues of $388.27 million, representing a year-over-year growth of 12.5% and 14.7%, respectively.
